MedTrace Logo

Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.

NCT05711459 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5405

Last updated 2023-02-03

No results posted yet for this study

Summary

The clinical trial is designed to evaluate the efficacy of bicyclol for patients with antineoplastic drug-induced liver injury and investigate factors effecting the therapeutic outcome.

Conditions

  • Drug-Induced Acute Liver Injury

Interventions

DRUG

Bicyclol tablets

Take Bicyclol tablets for the treatment of liver injury.

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Wei Lu, M.D · Tianjin Medical University Cancer Institute and Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-05-01
Completion
2024-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05711459 on ClinicalTrials.gov